🫁 Dexamethasone Single-Dose Croup Treatment Simulator

Single Oral Dexamethasone Dose at Triage

One weight-based oral dose is given as soon as croup is diagnosed.

• 0.6 mg/kg: Typical dose (oral, single dose)
• ~1–2 h: Onset (clinical effect begins)
• 36–72 h: Half-life (biologic activity)
• Oral: Route (or IM if vomiting)

Why a single dose

One dose is enough because dexamethasone has a long biologic half-life.

Absorption and distribution

Rapidly absorbed orally and distributed to inflamed airway tissue.

Glucocorticoid Receptor Anti-Inflammatory Action

Dexamethasone binds cytoplasmic receptors that dampen inflammatory gene expression.

• GR receptor: Target (cytoplasmic, ubiquitous)
• NF-κB inhibition: Key pathway (suppresses cytokines)
• IL-1, IL-6, TNF-α: Cytokines reduced (pro-inflammatory)
• ~25–30×: Potency (vs. cortisol)

Receptor binding cascade

Drug-receptor complex enters the nucleus and alters gene transcription.

Downstream suppression

Fewer inflammatory mediators are produced at the airway wall.

Placeholder: mechanism reduces vascular permeability and mucosal swelling.

Subglottic Mucosal Edema Subsides Over Hours

Airway wall swelling gradually decreases over the following hours.

• ~6 h: Peak effect (post-dose)
• ↑ over time: Airway diameter (as edema falls)
• ↓: Vascular leak (reduced permeability)
• up to 24 h+: Duration (sustained effect)

Timeline of edema decline

Swelling drops steadily as the anti-inflammatory effect builds.

Airflow restoration

Widening subglottic lumen restores easier airflow.

Stridor and Cough Improve as Edema Falls

Clinical croup score improves in parallel with mucosal healing.

• within hours: Westley score drop (placeholder)
• resolves first: Stridor at rest (placeholder)
• persists longer: Barky cough (placeholder)
• improves: Sleep/feeding (placeholder)

Symptom sequence

Stridor and retractions ease before the cough fully resolves.

Monitoring

Clinicians track croup score over the observation period.

Lower Rate of Repeat Emergency Visits

A single dose meaningfully lowers the chance of returning to care.

• substantial: Return-visit reduction (placeholder)
• ↓: Hospitalization (placeholder)
• rare: Repeat dosing needed (placeholder)
• favorable: Overall safety (placeholder)

Population-level benefit

Widespread single-dose use lowers overall return-visit burden.

Placeholder: one dose is now standard of care for croup severity.

Practical implications

Simple single-dose regimen improves adherence and outcomes.